Cerus Corporation investor relations material

Cerus Corporation operates as a biomedical products company. The company focuses on controlling the intrinsic systemic risk of blood transfusion. Its INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens, like viruses, bacteria and parasites that may be present in donated blood. The INTERCEPT red blood cell system is designed to inactivate blood-borne pathogens in donated red blood cells, white blood cells, and platelets. The system works by disrupting nucleic acids inside pathogens without affecting the viability or functionality of the red blood cells, white blood cells, or platelets.